Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial

CONCLUSION: Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.PMID:38450721 | DOI:10.1093/ejendo/lvae024

Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Blandine Gatta-Cherifi Kamel Mohammedi Tanguy Cariou Christine Poitou Philippe Touraine Gerald Raverot Thierry Brue Philippe Chanson Fr édéric Illouz Solange Grunenwald Olivier Chabre Emmanuel Sonnet Thomas Cuny Jer ôme Bertherat S ébastien Czernichow Source Type: research